Stryker (SYK) Stock Forecast, Price Target & Predictions
SYK Stock Forecast
Stryker stock forecast is as follows: an average price target of $305.00 (represents a -17.62% downside from SYK’s last price of $370.25) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
SYK Price Target
The average price target for Stryker (SYK) is $305.00 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $392.00 to $245.00. This represents a potential -17.62% downside from SYK's last price of $370.25.
SYK Analyst Ratings
According to 16 Wall Street analysts, Stryker's rating consensus is 'Buy'. The analyst rating breakdown for SYK stock is 0 'Strong Buy' (0.00%), 14 'Buy' (87.50%), 2 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Stryker Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Matt O\'Brien | Piper Sandler | $380.00 | $365.22 | 4.05% | 2.63% |
| Aug 28, 2024 | Ryan Zimmerman | BTIG | $374.00 | $358.51 | 4.32% | 1.01% |
| Aug 01, 2024 | Richard Newitter | Truist Financial | $345.00 | $327.00 | 5.50% | -6.82% |
| Jul 31, 2024 | Ryan Zimmerman | BTIG | $360.00 | $330.22 | 9.02% | -2.77% |
| May 30, 2024 | David Roman | Goldman Sachs | $372.00 | $341.14 | 9.05% | 0.47% |
| May 22, 2024 | David Toung | Argus Research | $380.00 | $330.51 | 14.97% | 2.63% |
| May 22, 2024 | Mike Matson | Needham | $392.00 | $330.51 | 18.60% | 5.87% |
| Apr 15, 2024 | Ryan Zimmerman | BTIG | $366.00 | $342.05 | 7.00% | -1.15% |
| Jan 31, 2023 | Matt O'Brien | Piper Sandler | $280.00 | $253.81 | 10.32% | -24.38% |
| Jan 06, 2023 | - | Morgan Stanley | $260.00 | $254.93 | 1.99% | -29.78% |
The latest Stryker stock forecast, released on Sep 10, 2024 by Matt O\'Brien from Piper Sandler, set a price target of $380.00, which represents a 4.05% increase from the stock price at the time of the forecast ($365.22), and a 2.63% increase from SYK last price ($370.25).
Stryker Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 8 |
| Avg Price Target | $377.00 | $364.75 | $371.13 |
| Last Closing Price | $370.25 | $370.25 | $370.25 |
| Upside/Downside | 1.82% | -1.49% | 0.24% |
In the current month, the average price target of Stryker stock is $377.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 1.82% increase as opposed to Stryker's last price of $370.25. This month's average price target is up 3.36% compared to last quarter, and up 1.58% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 09, 2024 | Wolfe Research | - | Outperform | Initialise |
| Aug 28, 2024 | UBS | Buy | Buy | Hold |
| Aug 28, 2024 | BTIG | Buy | Buy | Hold |
| Aug 01, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 31, 2024 | UBS | Buy | Buy | Hold |
| Jul 15, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 15, 2024 | BTIG | Buy | Buy | Hold |
| May 30, 2024 | Goldman Sachs | - | Neutral | Initialise |
| May 22, 2024 | Needham | Hold | Buy | Upgrade |
Stryker's last stock rating was published by Piper Sandler on Sep 10, 2024. The company gave SYK a "Overweight" rating, the same as its previous rate.
Stryker Financial Forecast
Stryker Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $5.82B | $4.91B | $5.00B | $4.78B | $5.20B | $4.48B | - | $4.28B | $4.70B | $4.16B | $4.29B | $3.95B | $4.26B | $3.74B | $2.76B | $3.59B | $4.13B | $3.59B |
| Avg Forecast | $7.44B | $6.26B | $6.35B | $6.14B | $6.86B | $5.78B | $5.87B | $5.68B | $6.35B | $5.37B | $5.40B | $5.10B | $5.60B | $4.87B | $4.83B | $4.57B | $4.96B | $4.47B | $4.53B | $4.18B | $4.65B | $4.22B | $4.14B | $3.95B | $4.33B | $3.41B | $2.59B | $3.57B | $4.11B | $3.58B |
| High Forecast | $7.49B | $6.30B | $6.40B | $6.18B | $6.91B | $5.83B | $5.91B | $5.72B | $6.40B | $5.41B | $5.44B | $5.14B | $5.64B | $4.91B | $4.86B | $4.60B | $5.00B | $4.50B | $4.53B | $4.27B | $4.74B | $4.31B | $4.23B | $4.03B | $4.41B | $3.48B | $2.65B | $3.64B | $4.19B | $3.65B |
| Low Forecast | $7.34B | $6.17B | $6.26B | $6.06B | $6.77B | $5.71B | $5.79B | $5.60B | $6.27B | $5.32B | $5.33B | $5.04B | $5.53B | $4.81B | $4.76B | $4.51B | $4.90B | $4.41B | $4.53B | $4.05B | $4.50B | $4.08B | $4.01B | $3.82B | $4.18B | $3.30B | $2.51B | $3.45B | $3.97B | $3.46B |
| # Analysts | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 9 | 13 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.01% | 1.04% | 1.05% | 1.05% | 1.00% | - | 1.02% | 1.01% | 0.99% | 1.04% | 1.00% | 0.98% | 1.10% | 1.07% | 1.00% | 1.01% | 1.00% |
Stryker's average Quarter revenue forecast for Mar 24 based on 9 analysts is $5.10B, with a low forecast of $5.04B, and a high forecast of $5.14B. SYK's average Quarter revenue forecast represents a -12.22% decrease compared to the company's last Quarter revenue of $5.82B (Dec 23).
Stryker EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 9 | 13 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.26B | $931.00M | $965.00M | $992.00M | $1.44B | $1.05B | - | $717.00M | $995.00M | $730.00M | $903.00M | $643.00M | $894.00M | $978.00M | $106.00M | $788.00M | $1.13B | $775.00M |
| Avg Forecast | $1.74B | $1.46B | $1.48B | $1.43B | $1.60B | $1.35B | $1.37B | $1.33B | $1.48B | $1.25B | $1.26B | $752.09M | $1.31B | $1.14B | $1.13B | $683.71M | $1.16B | $831.18M | $1.06B | $621.56M | $998.66M | $755.61M | $847.63M | $662.39M | $802.85M | $518.83M | $88.65M | $718.06M | $1.12B | $770.92M |
| High Forecast | $1.75B | $1.47B | $1.49B | $1.44B | $1.61B | $1.36B | $1.38B | $1.33B | $1.49B | $1.26B | $1.27B | $902.50M | $1.32B | $1.15B | $1.13B | $820.46M | $1.17B | $997.41M | $1.06B | $745.87M | $1.20B | $906.74M | $1.02B | $794.86M | $963.42M | $622.59M | $106.39M | $861.67M | $1.34B | $925.11M |
| Low Forecast | $1.71B | $1.44B | $1.46B | $1.41B | $1.58B | $1.33B | $1.35B | $1.31B | $1.46B | $1.24B | $1.24B | $601.67M | $1.29B | $1.12B | $1.11B | $546.97M | $1.14B | $664.94M | $1.06B | $497.25M | $798.93M | $604.49M | $678.10M | $529.91M | $642.28M | $415.06M | $70.92M | $574.45M | $893.77M | $616.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.82% | 0.86% | 1.45% | 1.24% | 1.26% | - | 1.15% | 1.00% | 0.97% | 1.07% | 0.97% | 1.11% | 1.89% | 1.20% | 1.10% | 1.01% | 1.01% |
9 analysts predict SYK's average Quarter EBITDA for Mar 24 to be $752.09M, with a high of $902.50M and a low of $601.67M. This is -40.17% lower than Stryker's previous annual EBITDA (Dec 23) of $1.26B.
Stryker Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 9 | 13 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $1.14B | $692.00M | $738.00M | $592.00M | $563.00M | $816.00M | - | $323.00M | $662.00M | $438.00M | $592.00M | $302.00M | $568.00M | $621.00M | $-83.00M | $493.00M | $725.00M | $466.00M |
| Avg Forecast | $1.80B | $1.34B | $1.37B | $1.23B | $1.63B | $1.22B | $1.24B | $1.10B | $1.51B | $1.07B | $1.08B | $386.82M | $1.26B | $938.34M | $917.50M | $351.66M | $1.09B | $498.71M | $875.76M | $319.69M | $664.43M | $453.37M | $555.70M | $311.11M | $510.09M | $329.44M | $-69.42M | $449.24M | $716.16M | $463.55M |
| High Forecast | $1.81B | $1.36B | $1.38B | $1.24B | $1.65B | $1.23B | $1.25B | $1.11B | $1.52B | $1.13B | $1.09B | $464.19M | $1.27B | $957.26M | $926.27M | $421.99M | $1.10B | $598.45M | $875.76M | $383.62M | $797.32M | $544.04M | $666.84M | $373.33M | $612.10M | $395.33M | $-55.53M | $539.09M | $859.39M | $556.26M |
| Low Forecast | $1.77B | $1.32B | $1.35B | $1.21B | $1.60B | $1.20B | $1.22B | $1.08B | $1.48B | $1.05B | $1.06B | $309.46M | $1.24B | $885.37M | $901.72M | $281.32M | $1.07B | $398.96M | $875.76M | $255.75M | $531.55M | $362.69M | $444.56M | $248.88M | $408.07M | $263.55M | $-83.30M | $359.39M | $572.93M | $370.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.74% | 0.80% | 1.68% | 0.52% | 1.64% | - | 1.01% | 1.00% | 0.97% | 1.07% | 0.97% | 1.11% | 1.89% | 1.20% | 1.10% | 1.01% | 1.01% |
Stryker's average Quarter net income forecast for Mar 24 is $386.82M, with a range of $309.46M to $464.19M. SYK's average Quarter net income forecast represents a -66.16% decrease compared to the company's last Quarter net income of $1.14B (Dec 23).
Stryker SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 9 | 13 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $1.94B | $1.70B | $1.71B | $1.78B | $1.75B | $1.46B | - | $1.71B | $1.75B | $1.60B | $1.50B | $1.57B | $1.56B | $1.24B | $1.23B | $1.33B | $1.38B | $1.29B |
| Avg Forecast | $2.69B | $2.26B | $2.29B | $2.22B | $2.48B | $2.09B | $2.12B | $2.05B | $2.30B | $1.94B | $1.95B | $2.05B | $2.02B | $1.76B | $1.74B | $1.86B | $1.79B | $1.82B | $1.64B | $1.69B | $1.75B | $1.66B | $1.41B | $1.62B | $1.40B | $659.94M | $1.02B | $1.21B | $1.36B | $1.28B |
| High Forecast | $2.71B | $2.28B | $2.31B | $2.23B | $2.50B | $2.11B | $2.14B | $2.07B | $2.31B | $1.96B | $1.97B | $2.46B | $2.04B | $1.78B | $1.76B | $2.23B | $1.81B | $2.19B | $1.64B | $2.03B | $2.10B | $1.99B | $1.70B | $1.95B | $1.68B | $791.93M | $1.23B | $1.45B | $1.64B | $1.54B |
| Low Forecast | $2.65B | $2.23B | $2.26B | $2.19B | $2.45B | $2.06B | $2.09B | $2.02B | $2.26B | $1.92B | $1.93B | $1.64B | $2.00B | $1.74B | $1.72B | $1.49B | $1.77B | $1.46B | $1.64B | $1.35B | $1.40B | $1.33B | $1.13B | $1.30B | $1.12B | $527.95M | $819.64M | $969.56M | $1.09B | $1.03B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.97% | 0.98% | 0.96% | 0.98% | 0.80% | - | 1.01% | 1.00% | 0.97% | 1.07% | 0.97% | 1.11% | 1.89% | 1.20% | 1.10% | 1.01% | 1.01% |
Stryker's average Quarter SG&A projection for Mar 24 is $2.05B, based on 9 Wall Street analysts, with a range of $1.64B to $2.46B. The forecast indicates a 5.51% rise compared to SYK last annual SG&A of $1.94B (Dec 23).
Stryker EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 12 | 8 | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 9 | 13 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $3.01 | $1.82 | $1.94 | $1.56 | $1.48 | $2.16 | - | $0.86 | $1.75 | $1.17 | $1.57 | $0.80 | $1.51 | $1.66 | $-0.22 | $1.32 | $1.94 | $1.24 |
| Avg Forecast | $4.66 | $3.49 | $3.56 | $3.20 | $4.23 | $3.16 | $3.22 | $2.84 | $3.92 | $2.77 | $2.79 | $2.36 | $3.27 | $2.43 | $2.38 | $2.00 | $2.84 | $2.20 | $2.27 | $1.95 | $2.72 | $2.28 | $2.14 | $1.99 | $2.55 | $1.41 | $0.56 | $1.81 | $2.46 | $1.90 |
| High Forecast | $4.71 | $3.52 | $3.59 | $3.23 | $4.28 | $3.19 | $3.25 | $2.87 | $3.96 | $2.94 | $2.82 | $2.38 | $3.30 | $2.48 | $2.40 | $2.02 | $2.86 | $2.22 | $2.27 | $2.00 | $2.79 | $2.34 | $2.19 | $2.04 | $2.61 | $1.45 | $0.57 | $1.85 | $2.52 | $1.95 |
| Low Forecast | $4.58 | $3.43 | $3.50 | $3.14 | $4.16 | $3.11 | $3.16 | $2.80 | $3.85 | $2.73 | $2.74 | $2.32 | $3.21 | $2.30 | $2.34 | $1.97 | $2.79 | $2.16 | $2.27 | $1.86 | $2.60 | $2.18 | $2.05 | $1.90 | $2.44 | $1.35 | $0.53 | $1.73 | $2.35 | $1.82 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.75% | 0.81% | 0.78% | 0.52% | 0.98% | - | 0.44% | 0.64% | 0.51% | 0.73% | 0.40% | 0.59% | 1.18% | -0.39% | 0.73% | 0.79% | 0.65% |
According to 9 Wall Street analysts, Stryker's projected average Quarter EPS for Mar 24 is $2.36, with a low estimate of $2.32 and a high estimate of $2.38. This represents a -21.74% decrease compared to SYK previous annual EPS of $3.01 (Dec 23).
Stryker Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| ZBH | Zimmer Biomet | $106.26 | $137.17 | 29.09% | Hold |
| MDT | Medtronic | $90.00 | $106.77 | 18.63% | Hold |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| STE | STERIS | $244.83 | $245.00 | 0.07% | Buy |
| ZIMV | ZimVie | $16.45 | $14.50 | -11.85% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
SYK Forecast FAQ
Is Stryker a good buy?
Yes, according to 16 Wall Street analysts, Stryker (SYK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 87.50% of SYK's total ratings.
What is SYK's price target?
Stryker (SYK) average price target is $305 with a range of $245 to $392, implying a -17.62% from its last price of $370.25. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Stryker stock go up soon?
According to Wall Street analysts' prediction for SYK stock, the company can go down by -17.62% (from the last price of $370.25 to the average price target of $305), up by 5.87% based on the highest stock price target, and down by -33.83% based on the lowest stock price target.
Can Stryker stock reach $600?
SYK's average twelve months analyst stock price target of $305 does not support the claim that Stryker can reach $600 in the near future.
What is Stryker's current price target trend?
2 Wall Street analysts forecast a $377 price target for Stryker (SYK) this month, up 1.82% from its last price of $370.25. Compared to the last 3 and 12 months, the average price target decreased by -1.49% and increased by 0.24%, respectively.
What are Stryker's analysts' financial forecasts?
Stryker's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.19B (high $24.37B, low $23.87B), average EBITDA is $5.64B (high $5.69B, low $5.57B), average net income is $5.19B (high $5.24B, low $5.1B), average SG&A $8.74B (high $8.81B, low $8.63B), and average EPS is $13.46 (high $13.59, low $13.23). SYK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $26.18B (high $26.37B, low $25.84B), average EBITDA is $6.11B (high $6.15B, low $6.03B), average net income is $5.75B (high $5.8B, low $5.65B), average SG&A $9.46B (high $9.53B, low $9.34B), and average EPS is $14.91 (high $15.05, low $14.65).
Did the SYK's actual financial results beat the analysts' financial forecasts?
Based on Stryker's last annual report (Dec 2022), the company's revenue was $18.45B, beating the average analysts forecast of $18.14B by 1.68%. Apple's EBITDA was $4.24B, beating the average prediction of $3.67B by 15.64%. The company's net income was $2.36B, missing the average estimation of $2.79B by -15.40%. Apple's SG&A was $6.46B, missing the average forecast of $6.95B by -7.08%. Lastly, the company's EPS was $6.23, missing the average prediction of $9.25 by -32.68%. In terms of the last quarterly report (Dec 2023), Stryker's revenue was $5.82B, beating the average analysts' forecast of $5.6B by 3.80%. The company's EBITDA was $1.26B, missing the average prediction of $1.31B by -3.83%. Stryker's net income was $1.14B, missing the average estimation of $1.26B by -9.27%. The company's SG&A was $1.94B, missing the average forecast of $2.02B by -4.11%. Lastly, the company's EPS was $3.01, missing the average prediction of $3.27 by -7.91%